

Table S1: Regions covered by the NGS panel.

Gene	Chr	Chr Start	Chr End	# Amplicons	Total Bases	Covered Bases	Missed Bases	Coverage (%)
APOB	chr2	21251194	21251415	2	222	222	0	100
APOB	chr2	21224597	21226211	10	1615	1615	0	100
APOB	chr2	21227947	21235528	43	7582	7582	0	100
APOB	chr2	21250695	21250942	2	248	248	0	100
APOB	chr2	21252765	21252892	1	128	128	0	100
APOB	chr2	21256166	21256395	2	230	230	0	100
APOB	chr2	21257683	21257778	1	96	96	0	100
APOB	chr2	21227136	21227329	1	194	194	0	100
APOB	chr2	21237940	21238137	1	198	198	0	100
APOB	chr2	21249655	21249841	1	187	187	0	100
APOB	chr2	21258451	21258585	1	135	135	0	100
APOB	chr2	21259967	21260132	1	166	166	0	100
APOB	chr2	21266731	21266822	1	92	92	0	100
APOB	chr2	21242590	21242782	1	193	193	0	100
APOB	chr2	21247800	21248001	1	202	202	0	100
APOB	chr2	21260825	21260988	1	164	164	0	100
APOB	chr2	21237315	21237470	1	156	156	0	100
APOB	chr2	21245698	21245919	1	222	222	0	100
APOB	chr2	21263805	21263960	1	156	156	0	100
APOB	chr2	21265228	21265353	1	126	126	0	100
APOB	chr2	21246392	21246569	1	178	178	0	100
APOB	chr2	21241859	21241990	1	132	132	0	100
APOB	chr2	21252506	21252662	1	157	157	0	100
APOB	chr2	21255221	21255458	2	238	238	0	100
APOB	chr2	21227428	21227552	1	125	125	0	100
APOB	chr2	21236027	21236410	2	384	384	0	100
APOB	chr2	21238237	21238422	1	186	186	0	100
APOB	chr2	21239306	21239526	1	221	221	0	100
APOB	chr2	21266380	21266428	1	49	49	0	100
APOE	chr19	45411012	45411214	2	243	243	0	100
APOE	chr19	45409854	45409929	2	116	116	0	100
APOE	chr19	45409121	45409185	2	105	105	0	100
APOE	chr19	45411785	45412512	5	768	768	0	100
LDLR	chr19	11200220	11200296	1	77	77	0	100
LDLR	chr19	11227530	11227679	1	150	150	0	100
LDLR	chr19	11210894	11211026	1	133	133	0	100
LDLR	chr19	11222185	11222320	1	136	136	0	100
LDLR	chr19	11230763	11230914	1	152	152	0	100
LDLR	chr19	11233845	11234025	1	181	181	0	100
LDLR	chr19	11221323	11221452	1	130	130	0	100
LDLR	chr19	11226765	11226893	1	129	129	0	100
LDLR	chr19	11231041	11231203	1	163	163	0	100
LDLR	chr19	11224206	11224443	2	238	238	0	100
LDLR	chr19	11218063	11218195	1	133	133	0	100
LDLR	chr19	11238679	11238766	1	88	88	0	100
LDLR	chr19	11213335	11213467	1	133	133	0	100
LDLR	chr19	11215891	11216281	3	391	391	0	100
LDLR	chr19	11223949	11224130	2	182	182	0	100
LDLR	chr19	11217236	11217368	1	133	133	0	100
LDLR	chr19	11240184	11240351	1	168	168	0	100

LDLR	chr19	11241952	11241997	1	46	46	0	100
LIPA	chr10	91005428	91005555	1	168	168	0	100
LIPA	chr10	90974580	90974823	2	284	284	0	100
LIPA	chr10	90984844	90984990	2	187	187	0	100
LIPA	chr10	91007290	91007410	1	161	161	0	100
LIPA	chr10	90982263	90982344	1	122	122	0	100
LIPA	chr10	90975690	90975771	1	122	122	0	100
LIPA	chr10	90983436	90983592	2	197	197	0	100
LIPA	chr10	90986647	90986766	2	160	160	0	100
LIPA	chr10	90987952	90988160	2	249	249	0	100
LDLRAP1	chr1	25889130	25889212	2	123	123	0	100
LDLRAP1	chr1	25870185	25870282	1	138	138	0	100
LDLRAP1	chr1	25881346	25881468	1	163	163	0	100
LDLRAP1	chr1	25891659	25891703	1	85	85	0	100
LDLRAP1	chr1	25893334	25893488	2	195	195	0	100
LDLRAP1	chr1	25890147	25890287	1	181	181	0	100
LDLRAP1	chr1	25880408	25880560	2	193	193	0	100
LDLRAP1	chr1	25883639	25883763	2	165	165	0	100
LDLRAP1	chr1	25889556	25889649	2	134	134	0	100
PCSK9	chr1	55523704	55523887	1	184	184	0	100
PCSK9	chr1	55525154	55525341	1	188	188	0	100
PCSK9	chr1	55517946	55518089	1	144	144	0	100
PCSK9	chr1	55518318	55518469	1	152	152	0	100
PCSK9	chr1	55509511	55509712	1	202	202	0	100
PCSK9	chr1	55521661	55521867	2	207	207	0	100
PCSK9	chr1	55522999	55523192	1	194	194	0	100
PCSK9	chr1	55527043	55527234	1	192	192	0	100
PCSK9	chr1	55505506	55505722	2	217	217	0	100
PCSK9	chr1	55512191	55512324	1	134	134	0	100
PCSK9	chr1	55529037	55529262	2	226	226	0	100
PCSK9	chr1	55524167	55524325	2	159	159	0	100

Table S2: Overall coverage of the main familial hypercholesterolemia associated genes.

Gene	Chr	Num Exons	Num Amplicons	Total Bases	Covered Bases	Missed Bases	Overall Coverage (%)
<i>APOB</i>	chr2	29	85	13982	13982	0	100
<i>LDLR</i>	chr19	18	21	2763	2763	0	100
<i>PCSK9</i>	chr1	12	16	2199	2199	0	100
<i>APOE</i>	chr19	4	11	1232	1232	0	100
<i>LDLRAP1</i>	chr1	9	14	1377	1377	0	100
<i>LIPA</i>	chr10	9	14	1650	1650	0	100

Table S3: Clinical characteristics of the cohort.

Patients	Smoker	DM	HBP	DL	BMI	FH	Highest LDLc
Woman 1	1	0	0	0	30,42	0	65
Woman 2	1	1	0	1	33,06	1	149
Woman 3	1	0	1	1	34,95	0	150
Woman 4	1	0	1	0	23,44	0	141
Woman 5	1	0	0	0	24,44	1	115
Woman 6	1	0	0	0	28,91	0	67
Woman 7	1	0	0	0	31,22	1	97
Woman 8	1	0	0	1	21,78	0	106
Man 1	1	0	0	0	29,05	0	148
Man 2	1	0	1	0	34,06	1	103
Man 3	0	0	1	0	27,76	0	109
Man 4	1	0	1	0	32,95	1	188
Man 5	0	0	0	0	26,3	1	98

Man 6	1	0	0	0	33,53	0	136
Man 7	1	0	1	1	32,79	0	115
Man 8	1	1	1	1	33,24	1	217
Man 9	0	0	0	1	27,04	0	179
Man 10	1	1	1	0	27,76	0	79
Man 11	1	0	0	0	-	0	75
Man 12	1	0	0	1	25,95	0	201
Man 13	1	0	0	1	23,44	0	207
Man 14	1	1	1	1	30,8	0	118
Man 15	1	0	0	0	33,63	0	117
Man 16	0	0	0	0	24,22	1	113
Man 17	1	0	0	1	34,72	1	137
Man 18	0	0	0	0	28,38	1	82
Man 19	1	1	0	0	29,07	0	137
Man 20	1	0	0	0	24,26	0	173
Man 21	1	0	0	1	27,38	0	161
Man 22	1	0	1	0	34,6	1	118
Man 23	1	0	0	1	26,12	0	177
Man 24	1	0	0	0	26,69	1	142
Man 25	0	0	0	0	24,22	0	80
Man 26	1	0	1	0	29,41	0	129
Man 27	1	0	1	0	27,68	0	190
Man 28	1	0	1	1	31,02	0	174
Man 29	1	0	0	0	31,79	0	79
Man 30	1	0	1	1	29,06	0	178
Man 31	1	0	0	0	33,22	0	89
Man 32	0	0	0	0	35,51	0	110
Man 33	1	0	0	0	22,27	0	100
Man 34	1	0	0	1	26,02	1	138
Man 35	1	0	0	0	31,14	0	109
Man 36	1	0	0	0	20,96	0	138
Man 37	1	0	0	0	32,45	0	118
Man 38	1	0	1	1	33,02	1	165
Man 39	1	1	0	0	30,67	0	128
Man 40	1	0	0	0	25,47	1	164
Man 41	1	0	0	1	27,75	0	197
Man 42	1	0	0	1	27,13	0	143
Man 43	1	0	1	0	32,28	0	129
Man 44	1	0	0	1	32,51	1	184
Man 45	0	0	0	0	29,41	0	94
Man 46	1	0	0	1	26,12	0	152
Man 47	1	0	0	1	25,95	0	205
Man 48	1	0	0	1	26,23	0	149

High blood pressure = HBP; DM = diabetes mellitus; DL = dyslipidemia; BMI = body mass index; FH = familial history of premature CVD; LDLc = LCL cholesterol; highest LDLc = highest available determination of untreated LDLc levels or corrected by lipid-lowering medication and its dose.

Table S4: DLCN Score distribution.

Patients	Clinical DLCN Score	Family history	Personal clinical history	Physical examination	LDLc punctuation	DNA analysis
Woman 1	2	0	2	0	0	negative
Woman 2	3	1	2	0	0	negative
Woman 3	2	0	2	0	0	negative
Woman 4	2	0	2	0	0	negative
Woman 5	3	1	2	0	0	negative
Woman 6	2	0	2	0	0	negative

Woman 7	3	1	2	0	0	negative
Woman 8	2	0	2	0	0	negative
Man 1	2	0	2	0	0	negative
Man 2	3	1	2	0	0	negative
Man 3	2	0	2	0	0	negative
Man 4	4	1	2	0	1	negative
Man 5	3	1	2	0	0	APOB p.Phe3150Leu
Man 6	2	0	2	0	0	negative
Man 7	2	0	2	0	0	negative
Man 8	6	1	2	0	3	LDLR p.Asp221Gly
Man 9	3	0	2	0	1	negative
Man 10	4	0	2	0	0	negative
Man 11	2	0	2	0	0	negative
Man 12	5	0	2	0	3	negative
Man 13	5	0	2	0	3	negative
Man 14	2	0	2	0	0	negative
Man 15	2	0	2	0	0	negative
Man 16	3	1	2	0	0	negative
Man 17	3	1	2	0	0	negative
Man 18	3	1	2	0	0	negative
Man 19	2	0	2	0	0	negative
Man 20	3	0	2	0	1	negative
Man 21	3	0	2	0	1	negative
Man 22	4	1	2	0	0	negative
Man 23	3	0	2	0	1	negative
Man 24	3	1	2	0	0	negative
Man 25	2	0	2	0	0	negative
Man 26	2	0	2	0	0	negative
Man 27	5	0	2	0	3	negative
Man 28	3	0	2	0	1	negative
Man 29	2	0	2	0	0	negative
Man 30	3	0	2	0	1	negative
Man 31	3	0	2	0	0	negative
Man 32	2	0	2	0	0	negative
Man 33	4	0	2	0	0	negative
Man 34	3	1	2	0	0	negative
Man 35	2	0	2	0	0	negative
Man 36	2	0	2	0	0	negative
Man 37	2	0	2	0	0	negative
Man 38	4	1	2	0	1	negative
Man 39	2	0	2	0	0	negative
Man 40	4	1	2	0	1	negative
Man 41	5	0	2	0	3	negative
Man 42	2	0	2	0	0	negative
Man 43	2	0	2	0	0	negative
Man 44	4	1	2	0	1	negative
Man 45	2	0	2	0	0	negative
Man 46	2	0	2	0	0	negative
Man 47	5	0	2	0	3	negative
Man 48	2	0	2	0	0	negative

DLCN= Dutch Lipid Clinic Network; LDLc= LCL cholesterol; LDLc punctuation= 155-189 mg/dL, 1 point; 190-249 mg/dL, 3 points; 250-329 mg/dL, 5 points; >329, 8 points.